External Source

Pralsetinib For Advanced Or Metastatic Ret-altered Thyroid Cancer With Dr. Vivek Subbiah

2021 58:12
Synopsis
Dr. Vivek Subbiah presents a lecture on "Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer ...

You Might Also Like

Vivek Subbiah, MD, on the FDA approved product, selpercatanib, for RET-driven lung & thyroid cancers 3:00
Vivek Subbiah, Md, On The Fda Approved Product, Selpercatani...
2020
Pralsetinib As A Therapeutic Option 0:51
Pralsetinib As A Therapeutic Option
2021
Pralsetinib As A Potential Agnostic Approach 0:56
Pralsetinib As A Potential Agnostic Approach
2021
Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC 1:07
Dr. Subbiah On The Fda Approval Of Pralsetinib In Ret+ Nsclc
2020
Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities to other therapies 1:37
Vivek Subbiah, Md, Describes Solid Tumor Tests For Ret Fusio...
2020
Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors 1:14
Dr. Subbiah On Safety And Efficacy Of Blu-667 In Ret-altered...
2018
RETEVMO FOR THYROID CANCER SAVES TANNER’S LIFE! 1:53
Retevmo For Thyroid Cancer Saves Tanner’s Life!
2020
FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancers 7:02
Fda Approval Of Selpercatinib For Ret Fusion Positive Nsclc ...
2020
RET Fusion Treatment: Pralsetinib - Targeted Therapies in Lung Cancer 2023 2:21
Ret Fusion Treatment: Pralsetinib - Targeted Therapies In Lu...
2023
Vivek Subbiah, MD, describes the incidence of RET-fusion and solid tumors amongst cancer patients 1:30
Vivek Subbiah, Md, Describes The Incidence Of Ret-fusion And...
2020
Vivek Subbiah, MD, on developing targeted therapies for RET fusion + solid tumors and effectivity 1:54
Vivek Subbiah, Md, On Developing Targeted Therapies For Ret ...
2020
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.